Cytostatic drug treatment causes seeding of gene promoter methylation

European Journal of Cancer

Volumn 43, Issue 5, 2007, Pages 947-954

  Bredberg, Anders ^a,b   Bodmer, Walter ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

6 Thioguanine; Colorectal cancer; DNA methylation; Drug resistance; HPRT

Indexed keywords

BISULFITE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; TIOGUANINE; TRANSCRIPTION FACTOR CDX1;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER RESISTANCE; CELL ACTIVATION; COLORECTAL CANCER; CONTROLLED STUDY; CPG ISLAND; CYTOSTASIS; DNA METHYLATION; EPIGENETICS; FEMALE; GENE ACTIVITY; GENE EXPRESSION; GENE INACTIVATION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROMOTER REGION;

ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; HOMEODOMAIN PROTEINS; HUMANS; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; LYMPHOCYTES; PROMOTER REGIONS (GENETICS); SULFITES; THIOGUANINE; TUMOR CELLS, CULTURED;

EID: 33847612419     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.12.003     Document Type: Article

References (23)

1. Gottesman M.M. How cancer cells evade chemotherapy. Cancer Res 53 (1993) 747-754
2. Glasspool R.M., Theodoridis J.M., and Brown R. Epigenetics as a mechanism driving polygenic clinical drug resistance. Br J Cancer 94 (2006) 1087-1092
3. Gifford G., Paul J., Vasey P.A., Kaye S.B., and Brown R. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res 10 (2004) 4420-4426
4. Nyce J.W. Drug-induced DNA hypermethylation: a potential mediator of acquired drug resistance during cancer chemotherapy. Mutation Res 386 (1997) 153-161
5. Theodoridis J.M., Strathdee G., and Brown R. Epigenetic silencing by CpG island methylation: potential as a therapeutic target and as a biomarker. Drug Res Update 7 (2004) 267-278
6. Wei S.H., Brown R., and Huang T.H. Aberrant DNA methylation in ovarian cancer: is there an epigenetic predisposition to drug response?. Ann NY Acad Sci 983 (2003) 243-250
7. Stokes T.L., Kunkel B.N., and Richards E.J. Epigenetic variation in Arabidopsis disease resistance. Genes Dev 16 (2002) 171-182
8. Steward N., Ito M., Yamaguchi Y., Koizumi N., and Sano H. Periodic DNA methylation in maize nucleosomes and demethylation by environmental stress. J Biol Chem 277 (2002) 37741-37746
9. Shimizu K., Kato A., Shigemura M., et al. Aberrant methylation patterns of the Rassf1a gene in rat lung adenocarcinomas induced by N-nitrosobis(2-hydroxypropyl)amine. Mol Carcinogen 45 (2005) 112-117
10. Sutherland J.E., and Costa M. Epigenetics and the environment. Ann NY Acad Sci 983 (2003) 151-160
11. Murphy S.P., Holtz R., Lewandowski N., Tomasi T.B., and Fuji H. DNA alkylating agents alleviate silencing of class II transactivator gene expression in L1210 lymphoma cells. J Immunol 169 (2002) 3085-3093
12. Barton T.S., Robaire B., and Hales B.F. Epigenetic programming in the preimplantaion rat embryo is disrupted by chronic paternal cyclophosphamide exposure. Proc Natl Acad Sci USA 102 (2005) 7865-7870
13. Bodmer W.F., Tripp M., and Bodmer J. Application of a fluorochromatic cytotoxicity assay to human leukocyte typing. In: Curtoni E.S. (Ed). Histocompatibility testing 1967 (1967), Munksgaard, Copenhagen 341-350
14. Wong N.A.C.S., Britton M.P., Choi G.S., et al. Loss of CDX1 expression in colorectal carcinoma: promoter methylation, mutation, and loss of heterozygosity analyses of 37 cell lines. Proc Natl Acad Sci USA 101 (2004) 574-579
15. Eshleman J.R., Markowitz S.D., Donover P.S., et al. Increased mutation rate at the hprt locus accompanies microsatellite instability in colon cancer. Oncogene 10 (1995) 33-37
16. Hou S.M., van Dam F.J., de Zwart F., et al. Validation of the human T-lymphocyte cloning assay - ring test report from the EU concerted action on HPRT mutation (EUCAHM). Mutation Res 431 (1999) 211-221
17. Stout J.T., and Caskey C.T. HPRT: gene structure, expression, and mutation. Ann Rev Genet 19 (1985) 127-148
18. Holliday R., and Ho T. DNA methylation and epigenetic inheritance. Methods 27 (2002) 179-183
19. Kang S.L., Kiefer C.M., and Yang T.P. Role of the promoter in maintaining transcriptionally active chromatin structure and DNA methylation patterns in vivo. Mol Cell Biol 23 (2003) 4150-4161
20. Song J.Z., Stirzaker C., Harrison J., Melki J.R., and Clark S.J. Hypermethylation trigger of the glutathione-S-transferase gene (GSTP1) in prostate cancer cells. Oncogene 21 (2002) 1048-1061
21. Stirzaker C., Song J.Z., Davidson B., and Clark S.J. Transcriptional gene silencing promotes DNA hypermethylation through a sequential change in chromatin modifications in cancer cells. Cancer Res 64 (2004) 3871-3877
22. Ushijima T., Watanabe N., Shimizu K., et al. Decreased fidelity in replicating CpG methylation patterns in cancer cells. Cancer Res 65 (2005) 11-17
23. Ushijima T. Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer 5 (2005) 223-231